Chromocell Therapeutics (CHRO) Insider Trading & Ownership $1.34 +0.08 (+6.35%) Closing price 07/1/2025Extended Trading$1.34 0.00 (0.00%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Chromocell Therapeutics (NYSE:CHRO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.40%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$17.21KNumber OfInsiders Selling(Last 12 Months)0 Get CHRO Insider Trade Alerts Want to know when executives and insiders are buying or selling Chromocell Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CHRO Insider Buying and Selling by Quarter Chromocell Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/12/2024Knuettel Francis IICEOBuy170$9.70$1,649.00 9/12/2024Richard MalamutDirectorBuy1,040$9.40$9,776.00 9/10/2024Knuettel Francis IICEOBuy650$8.90$5,785.00 (Data available from 1/1/2013 forward) CHRO Insider Trading Activity - Frequently Asked Questions Who is on Chromocell Therapeutics' Insider Roster? The list of insiders at Chromocell Therapeutics includes Knuettel Francis II, and Richard Malamut. Learn more on insiders at CHRO. What percentage of Chromocell Therapeutics stock is owned by insiders? 16.40% of Chromocell Therapeutics stock is owned by insiders. Learn more on CHRO's insider holdings. Which Chromocell Therapeutics insiders have been buying company stock? The following insiders have purchased CHRO shares in the last 24 months: Knuettel Francis II ($7,434.00), and Richard Malamut ($9,776.00). How much insider buying is happening at Chromocell Therapeutics? Insiders have purchased a total of 1,860 CHRO shares in the last 24 months for a total of $17,210.00 bought. Chromocell Therapeutics Key ExecutivesMr. Francis Knuettel II (Age 58)M.B.A., President, CEO, CFO, Treasurer, Secretary & Director Compensation: $107.5kDr. Eric Lang M.D. (Age 62)Chief Medical Officer Compensation: $264.99k More Insider Trading Tools from MarketBeat Related Companies Coeptis Therapeutics Insider Trading OnKure Therapeutics Insider Trading Kezar Life Sciences Insider Trading Synergy CHC Insider Trading Sonnet BioTherapeutics Insider Trading Clene Insider Trading SCYNEXIS Insider Trading FibroGen Insider Trading CalciMedica Insider Trading Generation Bio Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional SupportDo They Know Something? Insiders & Congress Buy UnitedHealthMicron Insiders Sell But Investors Should Buy, Buy, Buy This page (NYSE:CHRO) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredNew crypto laws coming. Will you win or lose?Washington’s first-ever “Crypto Week” could trigger a major Bitcoin surge — but one trader says don’t just buy...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat’s the “Golden Anomaly”… and how can you profit?Trump’s “Big Beautiful Bill” passed! That means the US is on track for $60 trillion in debt by 2035 – by the g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
